The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

The lawsuit, which was filed in U.S. District Court in New Jersey by a single investor, Eric Barta, is a class action on ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...

Novo Nordisk is the sole patent holder of semaglutide – the active ingredient in popular diabetes shot Ozempic and as well as blockbuster weight loss drug Wegovy. The company has said it is not ...

Researchers uncover ‘dangerous’ threat of global scam operation affecting millions as health regulators warn fraudulent ...

Benzinga reached out to Novo Nordisk’s media team but has not heard back. One study analyzed data from 424,152 diabetic patients, of which 106,454 were treated with Ozempic.

Novo Nordisk's opportunity for Ozempic, Wegovy, and Rybselsus remains huge. The sales of these drugs will almost certainly grow, even if Medicare exacts steep price cuts.

In 2023, sales from Novo Nordisk's GLP-1 diabetes therapies grew 52% year over year. Ozempic and a sibling treatment called Rybelsus are to thank for that growth.